Research ExplorerPublicationsIntravenous Artesunate for Imported Severe Malaria in Childr...

Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany: A Retrospective Study

Standard

Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany: A Retrospective Study. / Bélard, Sabine; Brand, Judith; Schulze-Sturm, Ulf; Janda, Ales; von Both, Ulrich; Tacoli, Costanza; Alberer, Martin; Kempf, Caroline; Stegemann, Miriam S; Krüger, Renate; Varnholt, Verena; Blohm, Martin; Reiter, Karl; Zoller, Thomas; Suttorp, Norbert; Mall, Marcus; von Bernuth, Horst; Gratopp, Alexander; Hübner, Johannes; Hufnagel, Markus; Kobbe, Robin; Kurth, Florian.

In: PEDIATR INFECT DIS J, Vol. 38, No. 11, 11.2019, p. e295-e300.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bélard, S, Brand, J, Schulze-Sturm, U, Janda, A, von Both, U, Tacoli, C, Alberer, M, Kempf, C, Stegemann, MS, Krüger, R, Varnholt, V, Blohm, M, Reiter, K, Zoller, T, Suttorp, N, Mall, M, von Bernuth, H, Gratopp, A, Hübner, J, Hufnagel, M, Kobbe, R & Kurth, F 2019, 'Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany: A Retrospective Study', PEDIATR INFECT DIS J, vol. 38, no. 11, pp. e295-e300. https://doi.org/10.1097/INF.0000000000002417

APA

Bélard, S., Brand, J., Schulze-Sturm, U., Janda, A., von Both, U., Tacoli, C., Alberer, M., Kempf, C., Stegemann, M. S., Krüger, R., Varnholt, V., Blohm, M., Reiter, K., Zoller, T., Suttorp, N., Mall, M., von Bernuth, H., Gratopp, A., Hübner, J., ... Kurth, F. (2019). Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany: A Retrospective Study. PEDIATR INFECT DIS J, 38(11), e295-e300. https://doi.org/10.1097/INF.0000000000002417

Vancouver

Bélard S, Brand J, Schulze-Sturm U, Janda A, von Both U, Tacoli C et al. Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany: A Retrospective Study. PEDIATR INFECT DIS J. 2019 Nov;38(11):e295-e300. https://doi.org/10.1097/INF.0000000000002417

Bibtex

@article{d5c7e778a0ef48b0a6d7a5e06bfb9393,
title = "Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany: A Retrospective Study",
abstract = "BACKGROUND: Intravenous artesunate (ivA) is the standard treatment for severe malaria. Data systematically evaluating the use of ivA in pediatric patients outside malaria-endemic regions are limited. The aim of this case series was to summarize efficacy and safety of ivA for imported severe malaria in children in Germany.METHODS: Our retrospective case series included pediatric patients with imported severe malaria treated with at least 1 dose of ivA (Artesun, Guilin Pharmaceutical; Shanghai, China) at 4 German tertiary care centers. Severe malaria was defined according to World Health Organization criteria.RESULTS: Between 2010 and 2018, 14 children with a median [interquartile range (IQR)] age of 6 (1;9.5) years were included. All children were of African descent. All but 2 patients had Plasmodium falciparum malaria; 1 child had P. vivax malaria and 1 child had P. falciparum and P. vivax co-infection. Median (IQR) parasitemia at admission in patients with P. falciparum was 9.5% (3;16.5). Patients were treated with 1-10 [median (IQR) 3 (3;4)] doses ivA. All but one patient received a full course of oral antimalarial treatment. Parasite clearance was achieved within 2-4 days, with the exception of 1 patient with prolonged clearance of peripheral parasitemia. Three patients experienced posttreatment hemolysis but none needed blood transfusion. Otherwise ivA was safe and well tolerated.CONCLUSIONS: ivA was highly efficacious in this pediatric cohort. We observed episodes of mild to moderate posttreatment hemolysis in approximately one-third of patients. The legal status and usage of potentially lifesaving ivA should be evaluated in Europe.",
author = "Sabine B{\'e}lard and Judith Brand and Ulf Schulze-Sturm and Ales Janda and {von Both}, Ulrich and Costanza Tacoli and Martin Alberer and Caroline Kempf and Stegemann, {Miriam S} and Renate Kr{\"u}ger and Verena Varnholt and Martin Blohm and Karl Reiter and Thomas Zoller and Norbert Suttorp and Marcus Mall and {von Bernuth}, Horst and Alexander Gratopp and Johannes H{\"u}bner and Markus Hufnagel and Robin Kobbe and Florian Kurth",
year = "2019",
month = nov,
doi = "10.1097/INF.0000000000002417",
language = "English",
volume = "38",
pages = "e295--e300",
journal = "PEDIATR INFECT DIS J",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

RIS

TY - JOUR

T1 - Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany: A Retrospective Study

AU - Bélard, Sabine

AU - Brand, Judith

AU - Schulze-Sturm, Ulf

AU - Janda, Ales

AU - von Both, Ulrich

AU - Tacoli, Costanza

AU - Alberer, Martin

AU - Kempf, Caroline

AU - Stegemann, Miriam S

AU - Krüger, Renate

AU - Varnholt, Verena

AU - Blohm, Martin

AU - Reiter, Karl

AU - Zoller, Thomas

AU - Suttorp, Norbert

AU - Mall, Marcus

AU - von Bernuth, Horst

AU - Gratopp, Alexander

AU - Hübner, Johannes

AU - Hufnagel, Markus

AU - Kobbe, Robin

AU - Kurth, Florian

PY - 2019/11

Y1 - 2019/11

N2 - BACKGROUND: Intravenous artesunate (ivA) is the standard treatment for severe malaria. Data systematically evaluating the use of ivA in pediatric patients outside malaria-endemic regions are limited. The aim of this case series was to summarize efficacy and safety of ivA for imported severe malaria in children in Germany.METHODS: Our retrospective case series included pediatric patients with imported severe malaria treated with at least 1 dose of ivA (Artesun, Guilin Pharmaceutical; Shanghai, China) at 4 German tertiary care centers. Severe malaria was defined according to World Health Organization criteria.RESULTS: Between 2010 and 2018, 14 children with a median [interquartile range (IQR)] age of 6 (1;9.5) years were included. All children were of African descent. All but 2 patients had Plasmodium falciparum malaria; 1 child had P. vivax malaria and 1 child had P. falciparum and P. vivax co-infection. Median (IQR) parasitemia at admission in patients with P. falciparum was 9.5% (3;16.5). Patients were treated with 1-10 [median (IQR) 3 (3;4)] doses ivA. All but one patient received a full course of oral antimalarial treatment. Parasite clearance was achieved within 2-4 days, with the exception of 1 patient with prolonged clearance of peripheral parasitemia. Three patients experienced posttreatment hemolysis but none needed blood transfusion. Otherwise ivA was safe and well tolerated.CONCLUSIONS: ivA was highly efficacious in this pediatric cohort. We observed episodes of mild to moderate posttreatment hemolysis in approximately one-third of patients. The legal status and usage of potentially lifesaving ivA should be evaluated in Europe.

AB - BACKGROUND: Intravenous artesunate (ivA) is the standard treatment for severe malaria. Data systematically evaluating the use of ivA in pediatric patients outside malaria-endemic regions are limited. The aim of this case series was to summarize efficacy and safety of ivA for imported severe malaria in children in Germany.METHODS: Our retrospective case series included pediatric patients with imported severe malaria treated with at least 1 dose of ivA (Artesun, Guilin Pharmaceutical; Shanghai, China) at 4 German tertiary care centers. Severe malaria was defined according to World Health Organization criteria.RESULTS: Between 2010 and 2018, 14 children with a median [interquartile range (IQR)] age of 6 (1;9.5) years were included. All children were of African descent. All but 2 patients had Plasmodium falciparum malaria; 1 child had P. vivax malaria and 1 child had P. falciparum and P. vivax co-infection. Median (IQR) parasitemia at admission in patients with P. falciparum was 9.5% (3;16.5). Patients were treated with 1-10 [median (IQR) 3 (3;4)] doses ivA. All but one patient received a full course of oral antimalarial treatment. Parasite clearance was achieved within 2-4 days, with the exception of 1 patient with prolonged clearance of peripheral parasitemia. Three patients experienced posttreatment hemolysis but none needed blood transfusion. Otherwise ivA was safe and well tolerated.CONCLUSIONS: ivA was highly efficacious in this pediatric cohort. We observed episodes of mild to moderate posttreatment hemolysis in approximately one-third of patients. The legal status and usage of potentially lifesaving ivA should be evaluated in Europe.

U2 - 10.1097/INF.0000000000002417

DO - 10.1097/INF.0000000000002417

M3 - SCORING: Journal article

C2 - 31626041

VL - 38

SP - e295-e300

JO - PEDIATR INFECT DIS J

JF - PEDIATR INFECT DIS J

SN - 0891-3668

IS - 11

ER -